Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)

Blood (2025) 146 (Supplement 1): 827.

https://doi.org/10.1182/blood-2025-827

Published: 2025

Journal Articles

Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas

Blood (2025) 146 (Supplement 1): 825.

https://doi.org/10.1182/blood-2025-825

Published: 2025

Journal Articles

Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement

Blood (2025) 146 (Supplement 1): 824.

https://doi.org/10.1182/blood-2025-824

Published: 2025

Journal Articles

Real world outcomes of bispecific T-cell engagers in plasma cell leukemia

Blood (2025) 146 (Supplement 1): 823.

https://doi.org/10.1182/blood-2025-823

Published: 2025

Journal Articles

Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma

Blood (2025) 146 (Supplement 1): 96.

https://doi.org/10.1182/blood-2025-96

Published: 2025

Journal Articles

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Surbhi Sidana, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Alexis Castaneda Puglianini, Gabriel De Avila, Christian Gordillo, Eli Zolotov, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen

Blood (2025) 146 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2025-1034

Published: 2025

Journal Articles

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

Blood (2025) 146 (Supplement 1): 671.

https://doi.org/10.1182/blood-2025-671

Published: 2025

Journal Articles

Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy

Blood (2025) 146 (Supplement 1): 397.

https://doi.org/10.1182/blood-2025-397

Published: 2025

Journal Articles

Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL

Blood (2025) 146 (Supplement 1): 5882.

https://doi.org/10.1182/blood-2025-5882

Published: 2025

Journal Articles

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 6375.

https://doi.org/10.1182/blood-2025-6375

Published: 2025

Journal Articles

Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4586.

https://doi.org/10.1182/blood-2025-4586

Published: 2025

Journal Articles

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 137.

https://doi.org/10.1182/blood-2025-137

Published: 2025

Journal Articles

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Ran Reshef, Alexandria Jensen, Christian Gordillo, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Puglianini, Gabriel De Avila, Eli Zolotov, Evguenia Bhurtel, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen, Surbhi Sidana

Blood (2025) 146 (Supplement 1): 134.

https://doi.org/10.1182/blood-2025-134

Published: 2025

Journal Articles

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Blood (2025) 146 (Supplement 1): 4069.

https://doi.org/10.1182/blood-2025-4069

Published: 2025

Journal Articles

From response to rupture: Evaluating GI perforation after CD19 CAR‑T in LBCL

Arash Velayati, Masooma Rana, Alexandria Jensen, Dasom (Caroline) Lee, Nima Ghalehsari, Anmol Goyal, Theresa Latchford, William Wang, Eric Heng, Wen-Kai Weng, Melody Smith, Sushma Bharadwaj, Matthew Frank, David Miklos, Saurabh Dahiya

Blood (2025) 146 (Supplement 1): 2771.

https://doi.org/10.1182/blood-2025-2771

Published: 2025

Journal Articles

Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 719.

https://doi.org/10.1182/blood-2025-719

Published: 2025

Journal Articles

Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 717.

https://doi.org/10.1182/blood-2025-717

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)

Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas

Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement

Real world outcomes of bispecific T-cell engagers in plasma cell leukemia

Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study

Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy

Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

From response to rupture: Evaluating GI perforation after CD19 CAR‑T in LBCL

Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma

Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only